KROS
Price
$18.03
Change
-$0.44 (-2.38%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
562.71M
28 days until earnings call
Intraday BUY SELL Signals
MEOBF
Price
$2.12
Change
+$0.22 (+11.58%)
Updated
Oct 9 closing price
Capitalization
2.23B
22 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KROS vs MEOBF

Header iconKROS vs MEOBF Comparison
Open Charts KROS vs MEOBFBanner chart's image
Keros Therapeutics
Price$18.03
Change-$0.44 (-2.38%)
Volume$19.75K
Capitalization562.71M
Mesoblast
Price$2.12
Change+$0.22 (+11.58%)
Volume$2K
Capitalization2.23B
KROS vs MEOBF Comparison Chart in %
View a ticker or compare two or three
VS
KROS vs. MEOBF commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KROS is a Hold and MEOBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (KROS: $18.47 vs. MEOBF: $1.59)
Brand notoriety: KROS and MEOBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KROS: 48% vs. MEOBF: 28%
Market capitalization -- KROS: $562.71M vs. MEOBF: $2.23B
KROS [@Biotechnology] is valued at $562.71M. MEOBF’s [@Biotechnology] market capitalization is $2.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KROS’s FA Score shows that 0 FA rating(s) are green whileMEOBF’s FA Score has 0 green FA rating(s).

  • KROS’s FA Score: 0 green, 5 red.
  • MEOBF’s FA Score: 0 green, 5 red.
According to our system of comparison, KROS is a better buy in the long-term than MEOBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KROS’s TA Score shows that 5 TA indicator(s) are bullish while MEOBF’s TA Score has 4 bullish TA indicator(s).

  • KROS’s TA Score: 5 bullish, 4 bearish.
  • MEOBF’s TA Score: 4 bullish, 1 bearish.
According to our system of comparison, MEOBF is a better buy in the short-term than KROS.

Price Growth

KROS (@Biotechnology) experienced а +0.93% price change this week, while MEOBF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.56%. For the same industry, the average monthly price growth was +1.40%, and the average quarterly price growth was +33.10%.

Reported Earning Dates

KROS is expected to report earnings on Mar 04, 2026.

MEOBF is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (-2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEOBF($2.23B) has a higher market cap than KROS($563M). KROS YTD gains are higher at: -9.283 vs. MEOBF (-16.316). KROS has higher annual earnings (EBITDA): 68.8M vs. MEOBF (-73.66M). KROS has more cash in the bank: 693M vs. MEOBF (161M). KROS has less debt than MEOBF: KROS (17.4M) vs MEOBF (128M). KROS has higher revenues than MEOBF: KROS (247M) vs MEOBF (17.2M).
KROSMEOBFKROS / MEOBF
Capitalization563M2.23B25%
EBITDA68.8M-73.66M-93%
Gain YTD-9.283-16.31657%
P/E Ratio11.84N/A-
Revenue247M17.2M1,436%
Total Cash693M161M430%
Total Debt17.4M128M14%
FUNDAMENTALS RATINGS
KROS vs MEOBF: Fundamental Ratings
KROS
MEOBF
OUTLOOK RATING
1..100
6599
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
6996
PRICE GROWTH RATING
1..100
4462
P/E GROWTH RATING
1..100
9954
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KROS's Valuation (59) in the null industry is in the same range as MEOBF (84). This means that KROS’s stock grew similarly to MEOBF’s over the last 12 months.

KROS's Profit vs Risk Rating (100) in the null industry is in the same range as MEOBF (100). This means that KROS’s stock grew similarly to MEOBF’s over the last 12 months.

KROS's SMR Rating (69) in the null industry is in the same range as MEOBF (96). This means that KROS’s stock grew similarly to MEOBF’s over the last 12 months.

KROS's Price Growth Rating (44) in the null industry is in the same range as MEOBF (62). This means that KROS’s stock grew similarly to MEOBF’s over the last 12 months.

MEOBF's P/E Growth Rating (54) in the null industry is somewhat better than the same rating for KROS (99). This means that MEOBF’s stock grew somewhat faster than KROS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KROSMEOBF
RSI
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
36%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
52%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
49%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
56%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
51%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
47%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Declines
ODDS (%)
Bearish Trend 8 days ago
77%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
KROS
Daily Signal:
Gain/Loss:
MEOBF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SPMAX10.110.10
+1.00%
Saratoga Mid Capitalization A
THOFX51.650.47
+0.92%
Thornburg Global Opportunities R5
KGDAX31.900.23
+0.73%
DWS Global Small Cap A
FTAWX14.53N/A
N/A
Fidelity Advisor Asset Manager 20% A
JRSAX12.34-0.13
-1.04%
JH Adaptive Risk Mgd U.S. Eq A

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INO. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
+0.38%
INO - KROS
53%
Loosely correlated
-0.59%
AXON - KROS
43%
Loosely correlated
-1.89%
CLDX - KROS
41%
Loosely correlated
+2.07%
ALT - KROS
39%
Loosely correlated
-1.44%
SPHDF - KROS
38%
Loosely correlated
N/A
More

MEOBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEOBF
1D Price
Change %
MEOBF100%
N/A
SPHDF - MEOBF
50%
Loosely correlated
N/A
AVTX - MEOBF
46%
Loosely correlated
+1.98%
COGT - MEOBF
39%
Loosely correlated
-1.79%
MESO - MEOBF
26%
Poorly correlated
+0.87%
KROS - MEOBF
26%
Poorly correlated
+0.38%
More